financetom
Business
financetom
/
Business
/
Infineon agrees to pay $837 mln to settle Qimonda dispute
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Infineon agrees to pay $837 mln to settle Qimonda dispute
Aug 29, 2024 1:57 AM

Aug 22 (Reuters) - German chipmaker Infineon

Technologies AG said on Thursday it has reached a

settlement with Qimonda AG's insolvency administrator by

agreeing to pay 753.5 million euros ($837.21 million), ending

the long-pending legal dispute.

Qimonda's administrator had sued Infineon in 2010 for 3.35

billion euros, arguing the chipmaker had transferred operations

to it at an inflated price.

The company was spun off from Infineon in 2006, but

collapsed in 2009 after chip prices plunged.

It filed for insolvency after failing to hammer out details

of a rescue package with its parent company.

The settlement agreement is for 753.5 million euros,

slightly lower than claimed 800 million euros, as Infineon is

submitting a declaration of subordination for already

established claims, for around 26.5 million euros, the

administrator said in a statement.

"As a result of the payments, Infineon will utilize the

provisions set aside for the legal dispute. The amount in excess

of this will have a negative impact on earnings and cash flow

from discontinued operations," Infineon said.

The administrator added the conclusion of insolvency

proceedings will be possible in 2025, with substantial dividends

for the creditors.

($1 = 0.9000 euros)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Invivyd's Pemgarda Added to NCCN Guidelines in Oncology for B-Cell Lymphomas
Invivyd's Pemgarda Added to NCCN Guidelines in Oncology for B-Cell Lymphomas
May 26, 2025
07:35 AM EDT, 05/23/2025 (MT Newswires) -- Invivyd ( IVVD ) said Friday its investigational monoclonal antibody Pemgarda has been added to the National Comprehensive Cancer Network's clinical practice guidelines in oncology for B-cell lymphomas. The product's inclusion in the cancer non-profit's guidelines recognizes it as a potential option for pre-exposure prophylaxis against COVID-19 in patients with B-cell malignancies, the...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Oncolytics Outline New Clinical Trial Data in Poster Presentation at ASCO Meeting
Oncolytics Outline New Clinical Trial Data in Poster Presentation at ASCO Meeting
May 26, 2025
07:30 AM EDT, 05/23/2025 (MT Newswires) -- Oncolytics Biotech ( ONCY ) on Friday said new data from the Phase I/II GOBLET clinical trial will be presented at a poster presentation at the American Society of Clinical Oncology (ASCO) meeting. The presentation highlights pelareorep's mechanism of action in pancreatic ductal adenocarcinoma (PDAC), and offers new insights into how this immunotherapy...
Trump Threatens Apple with 25% Tariff if iPhones Not Made in US
Trump Threatens Apple with 25% Tariff if iPhones Not Made in US
May 26, 2025
07:30 AM EDT, 05/23/2025 (MT Newswires) -- President Donald Trump said Friday that Apple ( AAPL ) will be hit with a tariff of at least 25% if iPhone production is not moved to the US. I have long ago informed Tim Cook of Apple ( AAPL ) that I expect their iPhone's that will be sold in the United...
Copyright 2023-2026 - www.financetom.com All Rights Reserved